Adjuvant immunotherapy recommendations for stage III melanoma: physician and nurse interviews

BACKGROUND: Adjuvant immunotherapy is revolutionising care for patients with resected stage III and IV melanoma. However, immunotherapy may be associated with toxicity, making treatment decisions complicated. This study aimed to identify factors physicians and nurses considered regarding adjuvant im...

Descripción completa

Detalles Bibliográficos
Autores principales: Livingstone, Ann, Dempsey, Kathy, Stockler, Martin R., Howard, Kirsten, Long, Georgina V., Carlino, Matteo S., Menzies, Alexander M., Morton, Rachael L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8434723/
https://www.ncbi.nlm.nih.gov/pubmed/34507552
http://dx.doi.org/10.1186/s12885-021-08752-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8434723/
https://www.ncbi.nlm.nih.gov/pubmed/34507552
http://dx.doi.org/10.1186/s12885-021-08752-1

Ejemplares similares